Check 35,000+ stocks against 26 valuation models and 37 quality factors

Nanosonics Limited (NNCSF) fair value: what the stock is really worth

As of Oct 2, 2026: fair value of Nanosonics Limited $2.22, price $2.04, upside +9.1%, quality 70 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

Fair value above price? Yes
Good quality? Yes
Add to watchlist

Healthcare · US · ISIN AU000000NAN9

Broad data Sep 24, 2026

Nanosonics Limited

NNCSF · US

NeutralQuality growthThe stock looks roughly fairly valued with average quality.

·Fair value $2.22 · Fairly valued (+9.1%)

✓Quality 70/100

✓Healthy Growth (revenue 5y +14.9 %/yr)

!Thin margins · 9.9% net margin (TTM)

✓Low debt · generates free cash flow

!Moderate moat 48/100

26 models, one by oneBear $1.52 to bull $2.89 Growth analysisrevenue history, year by year Quality 70/100 in detail37 factors, each one shown Compared with its peersrank on every measure, side by side

Watch Nanosonics Limited for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.

How to read this chart

60‑month range $1.69 – $5.16 · fair‑value band $1.52 – $2.89 · the $2.04 price screens below the $2.22 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Nanosonics Limited operates as an infection prevention company in Australia, North America, Europe, the United Kingdom, the Middle East, and Asia Pacific.

Nanosonics Limited operates as an infection prevention company in Australia, North America, Europe, the United Kingdom, the Middle East, and Asia Pacific. The company manufactures and distributes trophon ultrasound probe disinfector, and its related consumables and accessories; and research, develops, and commercialize of infection control and decontamination products and related technologies. It also provides trophon2 a device with an enhanced design and new functionality, including AcuTrace TM for audit-ready digital record-keeping and capabilities to connect trophon 2 with hospital IT systems; AuditPro nanosonics, an infection control workflow compliance management; Trophon EPR, a patented sonicated mist technology that provides high level disinfection of both endocavitary and surface ultrasound probes; and CORIS, an instrument reprocessing product platform. Nanosonics Limited was incorporated in 2000 and is headquartered in Macquarie Park, Australia.

Stock analysis

Nanosonics Limited (NNCSF) currently trades at $2.04, while our model-based Fair Value estimate is $2.22, so the stock looks roughly fairly valued today (gap 8.4%).

Valuation

Bull case: the Growth Earnings group reads highest at a median of $1.66 per share, and 5 of the 24 models we run sit above the $2.04 price.

Bear case: the Asset-Based group reads lowest at $0.3300, and 19 of the 24 models stay below the price. Evidence for this calculation is high.

Scenario range: $1.52 (bear) to $2.89 (bull), the price of $2.04 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 70/100 (solid quality), in the Healthcare sector.

Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.

Nanosonics Limited reported revenue of A$199M in FY2025 versus A$103M in FY2021, a compound +17.9%/yr. Reported net income was A$20.7M in FY2025, compounding +24.6%/yr from FY2021.

Key figures

Market cap $705M · P/E ratio 40.7 · P/S ratio 4.23 · EPS (TTM) $0.0500 · Net margin 10.4% · Return on equity 10.1% · Return on assets (EBIT) 4.7% · Operating margin 8.9%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 52 out of 100 (low confidence).

What moves the price

The share trades about 33% below its 52-week high and 5% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −37% fair-value upside, at 9%, NNCSF screens cheaper than that median.

Fair Value models

Bear $1.52 Fair Value $2.22 Bull $2.89

Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 12 months old). Earnings retained since then ($0.0500 per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.

Highest evidence

FCF DCF $1.53 $2.06 $3.65 78

Growth DCF $1.46 $2.17 $3.48 77

5Y EBITDA Exit $0.9900 $1.30 $1.90 75

All 24 models by family

DCF Models

FCF DCF $1.53 $2.06 $3.65 78

Owner Earnings $0.9200 $1.51 $2.60 74

5Y Revenue Exit $0.8900 $1.09 $1.51 74

5Y EBITDA Exit $0.9900 $1.30 $1.90 75

5Y P/E Exit $1.29 $2.29 $3.62 69

10Y Revenue Exit $1.10 $1.58 $1.78 68

10Y EBITDA Exit $1.17 $1.78 $2.72 68

10Y P/E Exit $1.38 $2.39 $3.98 62

Earnings-Based

Graham-Dodd $0.3300 $2.28 $3.20 63

Lynch FV $0.9100 $1.30 $1.68 61

PEG = 1.0 $0.9100 $1.30 $1.68 57

EPV $0.5100 $0.5300 $0.5500 74

Multiples

P/E Multiple $0.7900 $1.06 $1.32 63

P/S Multiple $0.6100 $0.8200 $1.02 58

P/B Multiple $0.6100 $0.8200 $1.02 55

EV/EBIT $0.6400 $0.7300 $0.8200 66

EV/EBITDA $0.7200 $0.8400 $0.9600 67

EV/Revenue $0.5600 $0.6500 $0.7300 54

Asset-Based

NCAV (Graham) $0.2400 $0.3300 $0.4900 54

Growth DCF

Growth DCF $1.46 $2.17 $3.48 77

Rev-Margin DCF $0.9000 $1.20 $1.78 73

Economic Profit

Residual Income $0.4000 $0.4400 $0.5000 71

ROIC Compounder $0.5300 $0.5900 $0.6200 72

Growth Earnings

Growth-Adj P/E $1.16 $1.66 $2.16 67

Open the full fair value analysis →

Notify me when NNCSF reaches fair value

Put NNCSF on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 70/100

Of which business quality 73 · Market factors (momentum, volatility) 17

Profitability 59

Margins and returns on capital today

Quality Growth 67

Are margins and returns improving?

Cashflow 82

Earnings quality: real cash, not paper profit

Fin. Strength 91

Balance sheet, leverage, solvency risk

Investment 51

Disciplined investing over empire-building

Low Volatility 25

Calm price path (market factor)

Momentum 18

Price trend over the last 3–12 months (market factor)

52W Momentum 6

Distance to the 52-week high (market factor)

Net Issuance 80

Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 90/100

Revenue growth appears healthy and is supported by profitability and cash-flow quality.

Revenue growth 1 year

+17.0%

Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

+18.4%

Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

+14.9%

Start year 2020 (pandemic). Over 10 years: +24.5% a year

Revenue growth 16 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

+49.7%

’14

’15

’16

’17

’18

’19

’20

’21

’22

’23

’24

’25

What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Basis: EBIT basis.

≈ −5.5%

Earnings growth per share plus dividend.

Earnings per share, growth per year−5.5%

Dividend (yield on the price)0.0%

Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.14.9% vs 66.0%, slowing

Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.12% → 5%

Start year 2020 (pandemic)

⚠ Rate on operating basis: 2025 sits 59% above its own trend.

Growth Forecast

A lot of optimism in the price

The price assumes about as much growth as the company has delivered so far and more than analysts expect.

What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).

+15.6%

Yearly growth needed for the next five years to justify today's price.

What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.

+6.7%

Yearly sales growth analysts expect, extended to five years.

After inflation (figures in AUD, Australia: IMF forecast 3.0% a year to 2030, 2.9% from 2016 to 2025) that is about +12.3% a year for the price and +3.6% for the forecasts.

Forecast 2026 (sales)+7.5%

Forecast 2027 (sales)+7.5%

Projected 2028 (sales)+6.8%

Projected 2029 (sales)+6.1%

Projected 2030 (sales)+5.5%

Watch NNCSF, get fair value alerts →

Compare Nanosonics Limited with another stock

Price, fair value, quality and upside side by side.

First stock

Second stock

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Instruments & Supplies · 185 stocks

Beats the industry median on 6/12 measures

A mixed picture versus its industry peers.

Valuation

Quality Score 70 · Top 25%

Fair Value upside −23.0% · Below median

Profitability

Return on equity (TTM) 10.1% · Above median

Return on assets 4.6% · Above median

Net margin (TTM) 9.9% · Above median

Operating margin (TTM) 8.9% · Below median

Growth and dividend

Revenue growth 9.2% · Above median

Valuation Multiplesvs Medical Instruments & Supplies median · lower = cheaper

P/E (TTM) 40.7× · Pricier than median

P/B 3.36× · Pricier than median

P/S (TTM) 3.40× · Pricier than median

P/FCF 20.0× · Cheaper than median

EV/EBITDA 22.1× · Priciest 25%

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Instruments & Supplies stocks, each showing price versus our Fair Value estimate.

Stock	Price	Fair Value	vs Fair Value
Intuitive Surgical, Inc ISRG	$406.63	$348.72	−14%
EssilorLuxottica Société anonyme EL	€144.60	€159.06	+10%
Becton, Dickinson and Company BDX	$178.07	$104.73	−41%
Medline Inc MDLN	$34.70	$29.06	−16%
Alcon Inc ALC	$63.94	$40.13	−37%
West Pharmaceutical Services, Inc WST	$375.65	$137.81	−63%
Sartorius Stedim Biotech S.A DIM	€208.20	€54.82	−74%
Straumann Holding STMN	CHF 89.80	CHF 45.50	−49%
Sartorius Aktiengesellschaft SRT	€206.50	€42.05	−80%
Solventum Corporation SOLV	$89.50	$134.36	+50%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued High-Quality Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks Undervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark

Run the numbers yourself: free valuation calculators

DCF Calculator Graham Number Peter Lynch Formula DDM Calculator Fama-French Model Intrinsic Value

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Nanosonics Limited · Fair Value
$2.22 +8%Fair Value
Calculator →

<a href="https://www.fairvalue-calculator.com/stock/NNCSF" target="_blank" rel="nofollow noopener" style="display:inline-flex;align-items:center;gap:12px;box-sizing:border-box;font-family:system-ui,-apple-system,Segoe UI,Roboto,sans-serif;text-decoration:none;background:#0f1814;color:#eaf2ed;border:1px solid #2a3a30;border-radius:12px;padding:12px 16px;max-width:360px"><span style="line-height:1.35"><span style="font-size:12px;color:#9fb0a8">Nanosonics Limited · Fair Value</span><br><b style="font-size:20px">$2.22</b> <span style="color:var(--fvc-g-mitte);font-weight:700;font-size:14px">+8%</span></span><span style="font-size:11px;color:var(--fvc-g-mitte);font-weight:700;margin-left:auto;text-align:right;line-height:1.3">Fair&nbsp;Value<br>Calculator&nbsp;→</span></a>

Cite: Fair Value Calculator (2026). "Nanosonics Limited Fair Value". https://www.fairvalue-calculator.com/stock/NNCSF

Frequently asked questions

Is Nanosonics Limited (NNCSF) overvalued or undervalued?

As of Sep 24, 2026, our model estimates a fair value of $2.22 versus a price of $2.04, about +9% upside (fairly valued).

What is the fair value of NNCSF?

Our model-based fair value for Nanosonics Limited is $2.22 (as of Sep 24, 2026), built from audited fundamentals. The current price: $2.04.

What is the quality score of NNCSF?

Nanosonics Limited has a Quality Score of 70/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.

What is the price target for Nanosonics Limited (NNCSF)?

Our model-based price target is the fair value of $2.22 (as of Sep 24, 2026) from 24 valuation models. Cautious scenario $1.52, optimistic scenario $2.89. It is a calculation from audited fundamentals, not an analyst target.

What is the Nanosonics Limited stock forecast for 2026?

Our models put fair value at $2.22, about +9% upside versus a price of $2.04 (fairly valued). Cautious scenario $1.52, optimistic scenario $2.89. The calculation is refreshed regularly with new filings.

What is the revenue of Nanosonics Limited (NNCSF)?

Nanosonics Limited reported trailing-twelve-month revenue of about A$207M (latest available figure, as of Sep 24, 2026).

What growth is priced into Nanosonics Limited (NNCSF)?

For today's price to be fair in a discounted-cash-flow model, Nanosonics Limited would have to grow free cash flow by +15.6 % per year for five years (discount rate 11.8 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +14.9 % per year. As of Sep 24, 2026.

What discount rate (WACC) does the fair value of NNCSF use?

Our models discount Nanosonics Limited at 11.8 %: a base by market capitalisation (small), damped by beta 1.21, country premium for USA. The same rate applies in all 26 models.

What is a reverse DCF?

A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Nanosonics Limited that is +15.6 % per year a year over ten years, using the same discount rate (11.8 %) and the same formula as our fair value.

How much growth has Nanosonics Limited (NNCSF) delivered so far?

Over the past 5 years revenue at Nanosonics Limited grew +14.9 % a year. The price currently implies +15.6 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.

How fast is the sector of Nanosonics Limited (NNCSF) growing?

The median revenue growth in the sector is +5.1 % a year. That is the yardstick for the growth priced into Nanosonics Limited (+15.6 % per year a year): it shows whether the expectation is within the usual range or beyond it.

What is the free cash flow yield of Nanosonics Limited (NNCSF)?

The free-cash-flow yield on the price is 3.90 %: that much free cash flow Nanosonics Limited produces per unit of market value. When it exceeds the discount rate of our models (11.8 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.

What is the intrinsic value of Nanosonics Limited (NNCSF)?

Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Nanosonics Limited it is $2.22 per share (as of Sep 24, 2026), against a price of $2.04. It is the blended result of 24 valuation models (cash flow, earnings, asset, dividend).

Is Nanosonics Limited stock overvalued or undervalued in 2026?

As of Sep 24, 2026, NNCSF trades below its calculated fair value: price $2.04, fair value $2.22, a gap of about +9% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.

Is fair value the same as the market price of NNCSF?

No. The price is what the market pays today ($2.04); the fair value is what the company's own numbers justify ($2.22). For Nanosonics Limited the two are $0.1860 per share apart. That gap is exactly why we show both numbers side by side.

How much is Nanosonics Limited worth?

The market values Nanosonics Limited at about $705M (market capitalisation, as of Sep 24, 2026). Per share that is $2.04; our models calculate a fair value of $2.22 per share.

What do the bullish and bearish scenarios say about NNCSF?

Our models span a range for Nanosonics Limited: cautious scenario $1.52, base $2.22, optimistic $2.89 per share (as of Sep 24, 2026, price $2.04). The range comes from different growth and margin assumptions, not from analyst opinions.

What is the P/E ratio of NNCSF?

Nanosonics Limited trades at a price-to-earnings ratio of 40.7 (as of Sep 24, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $2.22 is built from several models across several years. Other multiples: P/B 3.4, P/S 3.4, EV/EBITDA 22.1.

How solid is the balance sheet of Nanosonics Limited (NNCSF)?

Balance-sheet figures for Nanosonics Limited (as of Sep 24, 2026): return on equity 10.1%. They feed the Quality Score of 70/100, which measures business quality independently of the share price.

How far is NNCSF from its 52-week high?

Nanosonics Limited trades at $2.04, about 33% below its 52-week high of $3.06 and 5% above the low of $1.93 (as of Oct 2, 2026). Distance from the high says nothing about value: that is what the fair value of $2.22 is for.

Which stocks are comparable to Nanosonics Limited?

From the same area (Healthcare) we also value Intuitive Surgical, Inc, EssilorLuxottica Société anonyme, Becton, Dickinson and Company, Medline Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.

Is Nanosonics Limited stock attractive at the current price?

The data as of Sep 24, 2026: price $2.04, calculated fair value $2.22 (+9%), Quality Score 70/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.

How is the fair value of NNCSF calculated?

We run Nanosonics Limited through 24 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $2.22, with the spread shown as a cautious and an optimistic scenario.

Is it still worth investing in stocks now?

The global stock market currently sits 14.5 % above its aggregate fair value. Nanosonics Limited currently trades 8 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.

What is the share price of Nanosonics Limited (NNCSF)?

The closing price on Oct 2, 2026 was $2.04. Our model-based fair value is $2.22, about +9% upside (fairly valued). We carry closing prices from our data provider, not a live tick.

What should I pay attention to with Nanosonics Limited right now?

The price sits close to our fair value, market and models broadly agree here, little valuation tension. A fairly wide model range ($1.52 to $2.89) leaves room in how you read the outcome.

Key figures of Nanosonics Limited

How large is the market capitalisation of Nanosonics Limited (NNCSF)?

The market capitalisation of Nanosonics Limited is $705M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.

What is the P/S ratio of Nanosonics Limited (NNCSF)?

The price-to-sales ratio of Nanosonics Limited is 4.23 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.

What are the earnings per share of Nanosonics Limited (NNCSF)?

Earnings per share at Nanosonics Limited are $0.0500 (price ÷ EPS = P/E 40.7). Earnings per share over the last twelve months: total profit spread across every single share.

What is the net margin of Nanosonics Limited (NNCSF)?

The net margin of Nanosonics Limited is 10.4% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.

What is the return on equity of Nanosonics Limited (NNCSF)?

The return on equity (ROE) of Nanosonics Limited is 10.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.

What is the EBIT return on assets of Nanosonics Limited (NNCSF)?

On an EBIT basis the return on assets of Nanosonics Limited is 4.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.

What is the operating margin of Nanosonics Limited (NNCSF)?

The operating margin of Nanosonics Limited is 8.9% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.

How fast is revenue growing at Nanosonics Limited (NNCSF)?

Revenue at Nanosonics Limited is growing +9.2% versus a year earlier (3y avg +18.4%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.

How fast are earnings growing at Nanosonics Limited (NNCSF)?

Earnings per share at Nanosonics Limited are growing −1.3% versus a year earlier. How much earnings per share grew versus a year earlier.

How much net cash does Nanosonics Limited (NNCSF) hold?

Nanosonics Limited holds more cash than debt, A$154M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.

Free · no account needed

Watch Nanosonics Limited in the live analysis

One click puts Nanosonics Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.